These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33112366)

  • 1. Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis.
    Durgin JS; Jariwala NN; Wysocka M; Zhang KK; Maity A; Benoit B; Plastaras JP; Lewis DJ; Rosenthal JM; Teague JE; Berg S; Del Guzzo C; Kim EJ; Vittorio C; Haun PL; Samimi SS; Villasenor-Park J; Inverso J; Clark RA; Rook AH
    JAMA Dermatol; 2021 Jan; 157(1):90-95. PubMed ID: 33112366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response.
    Raphael BA; Shin DB; Suchin KR; Morrissey KA; Vittorio CC; Kim EJ; Gardner JM; Evans KG; Introcaso CE; Samimi SS; Gelfand JM; Rook AH
    Arch Dermatol; 2011 Dec; 147(12):1410-5. PubMed ID: 21844430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome.
    Richardson SK; Lin JH; Vittorio CC; Kim EJ; Yoon JS; Junkins-Hopkins J; Rook AH
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):226-32. PubMed ID: 17229339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome.
    Bouwhuis SA; Markovic SN; McEvoy MT; Pittelkow MR
    Mayo Clin Proc; 2002 Feb; 77(2):197-200. PubMed ID: 11838656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy.
    Wilson LD; Licata AL; Braverman IM; Edelson RL; Heald PW; Feldman AM; Kacinski BM
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):987-95. PubMed ID: 7607973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphoma.
    Elsayad K; Rolf D; Sunderkötter C; Weishaupt C; Müller EC; Nawar T; Stranzenbach R; Livingstone E; Stadler R; Steinbrink K; Moritz RKC; Eich HT
    J Dtsch Dermatol Ges; 2022 Mar; 20(3):279-285. PubMed ID: 34984837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
    Sethi TK; Montanari F; Foss F; Reddy N
    Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythrodermic mycosis fungoides and Sézary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: A single-centre experience.
    Atzmony L; Amitay-Laish I; Gurion R; Shahal-Zimra Y; Hodak E
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2382-9. PubMed ID: 26299651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response.
    Vonderheid EC; Bigler RD; Greenberg AS; Neukum SJ; Micaily B
    Am J Clin Oncol; 1994 Jun; 17(3):255-63. PubMed ID: 8192114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total Skin Electron Beam Therapy as Part of Multimodal Treatment Strategies for Primary Cutaneous T-Cell Lymphoma.
    Elsayad K; Susek KH; Eich HT
    Oncol Res Treat; 2017; 40(5):244-252. PubMed ID: 28448985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and sub-acute toxicity profile of ultra-hypofractionated low-dose total skin electron beam with two 4 Gy fractions for cutaneous T cell lymphoma.
    Rolf D; Elsayad K; Eich HT
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1757-1761. PubMed ID: 33219856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
    Stevens SR; Baron ED; Masten S; Cooper KD
    Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sézary syndrome: diagnostic criteria and therapeutic options.
    Russell-Jones R; Whittaker S
    Semin Cutan Med Surg; 2000 Jun; 19(2):100-8. PubMed ID: 10892711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome.
    Elsayad K; Kroeger K; Greve B; Moustakis C; Assaf C; Stadler R; Lenz G; Weishaupt C; Eich HT
    Strahlenther Onkol; 2020 Jan; 196(1):77-84. PubMed ID: 31591658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracorporeal photopheresis and multimodality therapy in patients with T-cell cutaneous lymphomas: Real-life experience in Argentina.
    Baquero Rey JA; Zambrano Franco EA; Andrade Miranda A; Marciano S; Mazzuoccolo LD; Enz PA
    J Clin Apher; 2021 Dec; 36(6):815-822. PubMed ID: 34478581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.
    Richardson SK; McGinnis KS; Shapiro M; Lehrer MS; Kim EJ; Vittorio CC; Junkins Hopkins JM; Rook AH
    J Cutan Med Surg; 2003; 7(4 Suppl):8-12. PubMed ID: 12958701
    [No Abstract]   [Full Text] [Related]  

  • 18. Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis.
    Kamstrup MR; Gniadecki R; Iversen L; Skov L; Petersen PM; Loft A; Specht L
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):138-43. PubMed ID: 25863761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study on the evolution of the T-cell repertoire in patients with Sézary syndrome treated by extracorporeal photopheresis.
    Ingen-Housz-Oro S; Bussel A; Flageul B; Michel L; Dubertret L; Kourilsky P; Gachelin G; Bachelez H; Musette P
    Blood; 2002 Sep; 100(6):2168-74. PubMed ID: 12200382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome.
    Fritz TM; Kleinhans M; Nestle FO; Burg G; Dummer R
    Br J Dermatol; 1999 Jun; 140(6):1144-7. PubMed ID: 10354086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.